Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society Conference - Efficacy and Safety of Avacopan Versus

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

278.4 USD

Average target price

304.4 USD

Spread / Average Target

+9.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	+9.17%	149B
ELI LILLY AND COMPANY	+26.10%	681B
NOVO NORDISK A/S	+21.14%	556B
JOHNSON & JOHNSON	-5.23%	361B
MERCK & CO., INC.	+17.00%	325B
ABBVIE INC.	+5.10%	285B
ASTRAZENECA PLC	+13.72%	235B
NOVARTIS AG	+4.02%	199B
ROCHE HOLDING AG	-11.45%	189B
PFIZER, INC.	-3.98%	157B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:20:15 2024-05-03 am EDT			5-day change	1st Jan Change
315.3 ^USD	+13.27%		+16.46%	+9.17%

03:33pm	Wall St opens sharply higher on soft jobs data	RE
03:16pm	News Highlights : Top Company News of the Day - Friday at 9 AM ET	DJ

Wall St opens sharply higher on soft jobs data	09:33am	RE
News Highlights : Top Company News of the Day - Friday at 9 AM ET	09:16am	DJ
Wall St set to open sharply higher on soft jobs data	08:58am	RE
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	07:27am	MT
Apple, Jobs Report Boost Wall Street Pre-Bell; Asia Mixed, Europe Up	07:19am	MT
News Highlights : Top Company News of the Day - Friday at 7 AM ET	07:17am	DJ
William Blair Upgrades Amgen to Outperform From Market Perform	07:16am	MT
Stock Futures Robust Pre-Bell Ahead of April Jobs Report; Asia Churns, Europe Gains	07:14am	MT
Leerink Adjusts Price Target on Amgen to $352 From $324, Keeps Market Perform Rating	06:55am	MT
Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance Premarket	06:41am	MT
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data	06:36am	RE
Amgen shares jump after teasing weight-loss drug data, rivals slip	06:16am	RE
North American Morning Briefing : Apple, Amgen -2-	06:09am	DJ
North American Morning Briefing : Apple, Amgen Boost Stock Futures; All Eyes on Jobs Report	06:08am	DJ
Futures rise on Apple, Amgen boost; jobs data on tap	06:05am	RE
Amgen Lifts Low-End of Full-Year Revenue Outlook; 'Encouraged' by Interim Data of Potential Obesity Drug	06:00am	MT
Barclays Upgrades Amgen to Equalweight From Underweight, Adjusts Price Target to $300 From $230	05:53am	MT
Morgan Stanley Adjusts Price Target on Amgen to $310 From $271, Keeps Equalweight Rating	05:53am	MT
RBC Adjusts Price Target on Amgen to $328 From $332, Keeps Outperform Rating	05:53am	MT
BMO Capital Adjusts Price Target on Amgen to $355 From $336, Keeps Outperform Rating	05:52am	MT
Goldman Sachs Adjusts Price Target on Amgen to $350 From $359, Keeps Buy Rating	05:52am	MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	05:48am
Amgen: slight decline in Q1 EPS	04:35am	CF
Amgen Expects Full-Year 2024 Share Repurchases Not to Exceed $500 Million	May. 02	MT
Amgen Q1 Non-GAAP Earnings Decline, Revenue Increases; Adjusts Full-Year Guidance; Shares Advance After Hours	May. 02	MT